Literature DB >> 26398829

A Case of Atypical Carcinoid: Harboring Variant 3a/b EML4-ALK Rearrangement.

Aya Fukuizumi1, Kiwamu Akagi, Hiroshi Sakai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26398829     DOI： 10.1097/JTO.0000000000000635

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

1.  A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Authors:  Na Liu; Jingjing Wang; Xiao Fu; Xiaoqiang Zheng; Huan Gao; Tao Tian; Zhiping Ruan; Yu Yao
Journal:  Cancer Biol Ther       Date:  2019-09-27       Impact factor: 4.742

2.  Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors:  Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal:  Oncotarget       Date:  2022-06-01

3.  Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor.

Authors:  Masayuki Nakajima; Naoki Uchiyama; Rie Shigemasa; Takeshi Matsumura; Ryota Matsuoka; Akihiro Nomura
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

Review 4.  Systemic treatment for lung carcinoids: from bench to bedside.

Authors:  Mariangela Torniai; Laura Scortichini; Francesca Tronconi; Corrado Rubini; Francesca Morgese; Silvia Rinaldi; Paola Mazzanti; Rossana Berardi
Journal:  Clin Transl Med       Date:  2019-07-04

5.  ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature.

Authors:  Qiang Zheng; Mingjia Zheng; Yan Jin; Xuxia Shen; Ling Shan; Lei Shen; Yihua Sun; Haiquan Chen; Yuan Li
Journal:  Onco Targets Ther       Date:  2018-08-17       Impact factor: 4.147

Review 6.  Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.

Authors:  Michele Prisciandaro; Maria Antista; Alessandra Raimondi; Francesca Corti; Federica Morano; Giovanni Centonze; Giovanna Sabella; Alessandro Mangogna; Giovanni Randon; Filippo Pagani; Natalie Prinzi; Monica Niger; Salvatore Corallo; Erica Castiglioni di Caronno; Marco Massafra; Maria Di Bartolomeo; Filippo de Braud; Massimo Milione; Sara Pusceddu
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

7.  Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA.

Authors:  Denise A Gococo-Benore; Ashton Boyle; Natasha Wylie; Leylah Drusbosky; Andras Khoor; Jason S Starr
Journal:  Cureus       Date:  2022-02-16

8.  Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature.

Authors:  Xi Lei; Shuai Zhu; Dian Ren; Fan Ren; Tong Li; Ning Zhou; Shuo Li; Tao Shi; Lingling Zu; Zuoqing Song; Justyna Chalubinska-Fendler; Marc G Denis; Eric H Bernicker; Vincent Thomas de Montpréville; Richeng Jiang; Song Xu
Journal:  Transl Lung Cancer Res       Date:  2022-06

9.  Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.

Authors:  Nobuyoshi Hayashi; Akihisa Fujita; Toyohiro Saikai; Hirotugu Takabatake; Mie Sotoshiro; Kyuutarou Sekine; Akihiko Kawana
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.